ClinicalTrials.gg
Active, not recruitingNCT07291284Updated Dec 26, 2025

Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis

A Phase 3 interventional study of LP-003 and Placebo in Seasonal Allergic Rhinitis, sponsored by Longbio Pharma. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-26.

Sponsored by Longbio Pharma · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as active, not recruiting.
  • Registered 1 year 4 months after the study started (first participant enrolled Aug 2024, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
546
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies in Rhinitis, Allergic, Seasonal with a site in China — 12 open to participants now, 14 under way, 8 of them phase 3. Rhinitis, Allergic, Seasonal · China.

Enrollment
6th of 27
546 · median 160
Started
2024
with 2 others
Phase 3
10 of 27
5 open now
Primary completion
2026-03
later than 2 of 13 live
Registered
21st of 27
by date
Lead sponsor
2 of 27
Longbio Pharma

Among the 27 studies in Rhinitis, Allergic, Seasonal with a site in China, this one is the 6th largest by enrollment, is one of 3 that started in 2024, is one of 10 in phase 3, reaches primary completion later than 2 of the 13 other live ones, and was the 21st registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

12 of the 27 studies in Rhinitis, Allergic, Seasonal with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Rhinitis, Allergic, Seasonal with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of LP-003 injection in patients with moderate to severe seasonal allergic rhinitis inadequately controlled by standard-of-care.

03

Conditions studied

  • Seasonal Allergic Rhinitis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 18 to 65 years
  • Subjects with SAR for at least 2 years
  • At least one serum-specific IgE test for an allergen associated with the onset of allergic rhinitis during the current season or the same period
  • Subjects who did not achieve satisfactory efficacy from Standard-of-Care prior to screening
  • Subjects who experienced nasal symptoms for ≥ 2 days, or nasal and ocular symptoms for ≥ 1 day; with rTNSS ≥ 1 prior to randomization

Exclusion criteria

Exclusion Criteria:

  • Combined with non-allergic rhinitis, such as drug-induced rhinitis, vasomotor rhinitis, non-allergic rhinitis with eosinophilia syndrome, a history of acute or chronic sinusitis
  • Subjects with perennial allergic rhinitis (PAR)
  • Underwent any nasal or sinus surgery within 1 year prior to screening
  • Presence of glaucoma, cataract, ocular herpes simplex, infectious conjunctivitis, or other ocular infections
  • conditions upon the judgement of investigator
  • Subjects with concomitant asthma who, upon the judgement of investigator, require inhaled treatment during the study
  • The laboratory results at screening: a) white blood cell (WBC) \< 2.5×10\^9/L; b) (AST) or alanine aminotransferase (ALT) > 2.0 × (ULN) or total > 1.5 ×ULN; c) Serum creatinine (Cr) > 1.5 × ULN
  • Received treatment with similar drugs (e.g., Omalizumab) or used LP-003 Injection within 6 months prior to screening
  • Received systemic glucocorticoids within 4 weeks prior to screening
  • Received intranasal glucocorticoids, mast cell membrane stabilizers, tricyclic antidepressants, leukotriene receptor antagonists, or antihistamine medications within 1 week prior to randomization
  • Received traditional Chinese medicine treatment for allergic rhinitis within the 7 days prior to randomization
  • Received allergen immunotherapy within 6 months prior to screening (for those who have not completed the therapy), or within 3 years prior to screening (for those who have completed the therapy)
  • Subjects for whom exposure to allergens in the home or work environment are expected to undergo significant changes during the trial, as assessed by the investigator, which may interfere with the evaluation of efficacy
  • Subjects planning to travel outside their area of residence during the trial to an area without pathogenic pollen, for either 2 consecutive days or a total duration exceeding three days
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
546 participants (actual)

Study arms

  • Experimental
    Experimental: LP-003

    Participants received subcutaneous of LP-003 Injection at a dose of 100 mg once every 4 weeks.

    Biological: LP-003

  • Placebo comparator
    Placebo Comparator:Placebo

    Participants received subcutaneous of Placebo Injection once every 4 weeks.

    Biological: Placebo

Interventions

  • BiologicalLP-003

    Participants were administered LP-003 via subcutaneous injection every 4 weeks.

  • BiologicalPlacebo

    Participants were administered Placebo via subcutaneous injection every 4 weeks

06

What researchers measure

Primary outcomes

  1. Mean daily reflective total nasal symptom score (rTNSS) during the pollen peak period (PPP)

    The rTNSS is a patient self-reported questionnaire of four nasal symptoms: nasal itching, nasal congestion, sneezing and rhinorrhea. Patients will report their symptoms reflected or felt over the last 12 hours. Each symptom is scored on a 0-3 scale (0 = no symptoms, 1 = mild, 2 = moderate, 3 = severe). The total score is the sum of the four items, ranging from 0 to 12, with higher scores indicating greater symptom severity.

    Time frame: Up to 4 Months

Secondary outcomes

  1. Mean daily rTNSS during the pollen period (PP)

    Time frame: Up to 4 Months

  2. Mean daily instantaneous total nasal symptom score (iTNSS) during the PPP

    Time frame: Up to 4 Months

  3. Mean daily iTNSS during the PP

    Time frame: Up to 4 Months

  4. Mean daily rTNSS combined with rescue medication score (DNSMS) during the PPP

    Integrates daily rTNSS (4 nasal symptoms, 0-3 each, total 0-12) and rescue medication score (0 for no rescue use and 1 for rescue use).

    Time frame: Up to 4 Months

  5. Mean daily total ocular symptom score (TOSS) during the PPP

    It is derived from 2 individual ocular symptoms (itching/burning/redness, and tearing/watering), and each symptom is scored on a 0-3 scale. The daily TOSS is the sum of the two items, ranging from 0 (no symptoms) to 6 (maximum severity) per day.

    Time frame: Up to 4 Months

  6. Mean daily TOSS combined with rescue medication score (DNOMS) during the PPP

    Integrates daily TOSS (2 individual ocular symptoms, 0-3 each, total 0-6) and rescue medication score (0 for no rescue use and 1 for rescue use).

    Time frame: Up to 4 Months

  7. Mean daily rescue medication score (RMS) during the PPP

    The RSM is assessed based on the usage of montelukast sodium tablets, with a scoring rule of 0 points for no use and 1 point for use on the day. The mean daily RSM during the PPP is calculated as the sum of the cumulative RSM during the PPP divided by the number of days in the PPP.

    Time frame: Up to 4 Months

  8. Incidence of adverse events (AEs)

    Time frame: Up to Week 28

07

Study locations

1 site
  • Beijing Shijitan Hospital, Capital Medical University (the formerly Beijing Railway General Hospital)
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Mar 2026, 19 months after the start.

Of 31 industry-sponsored phase 3 interventional studies under Rhinitis, Allergic, Seasonal, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's planned 19 months is above that.

Counting every sponsor, half of 37 studies reached it within 4 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2025
First posted
Dec 18, 2025
StartActual
Aug 1, 2024
Primary completionEst.
Mar 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Dec 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07291284
Lead sponsor
Longbio Pharma
Responsible party
Sponsor
First posted
Dec 18, 2025
Start date
Aug 1, 2024
Primary completion
Mar 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 26, 2025

Study contacts

Xueyan Wang
principal investigator · Beijing Shijitan Hospital, Capital Medical University (the formerly Beijing Railway General Hospital)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LP-003

Start the discussion